NEW YORK — Aiforia said on Monday that it has received a €2.1 million ($2.3 million) grant to continue development of its artificial intelligence-based digital pathology technologies for primary cancer diagnosis.
According to the Finnish company, the grant was awarded under the European Union's Horizon 2020 program and will be used to develop deep learning AI models that can help diagnose common cancer types including prostate and lung cancers.
Aiforia also said that it has received CE-IVD marking for Aiforia Clinical pathology image analysis platform, which is now available in Europe for diagnostic use. The platform, which can be integrated into a hospital's IT infrastructure, allows pathologists to make a primary visual diagnosis from digitized tissue samples, the company said.
Aiforia is a spinout of the Finnish Institute for Molecular Medicine and develops imaging-based diagnostics. It said that it is developing deep learning AI models for clinical use.